A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Dabigatran Impurity 103 - Request Quote

Picture of Dabigatran Impurity 103

Dabigatran Impurity 103

SZ CAT No:SZ-D012214
CAS No
NA
Mol.F.
C26H22N6O4
Mol.Wt.
482.5
Inv. Status
Synthesis on demand

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Dabigatran Impurity 103 is chemically 4-(2-((4-Cyanophenyl)amino)-N-methylacetamido)-3-(2-((4-cyanophenyl)amino)acetamido)benzoic acid. Dabigatran Impurity 103 is supplied with detailed characterization data compliant with regulatory guideline. Dabigatran Impurity 103 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Dabigatran.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

buy high quality Dabigatran Impurity 103

Purchase Dabigatran Impurity 103

Dabigatran Impurity 103 suppliers

Dabigatran Impurity 103 manufacturers

Dabigatran Impurity 103 price

Order Dabigatran Impurity 103

Enquire Dabigatran Impurity 103

Dabigatran Impurity 103 cost

Dabigatran Impurity 103 Supplier

Dabigatran Impurity 103 Distributor

Dabigatran Impurity 103 for Method Validation

Dabigatran Reference Standard

Dabigatran Impurity 103 for ANDA Filing

Dabigatran Impurity 103 for Forced Degradation Studies

Dabigatran Impurity 103 Identification Standards

Dabigatran Impurity 103 for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,